Login

QA-68

CAT:
804-HY-150797
Size:
Inquire
Price:
Ask
For price, please contact [email protected]
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
QA-68 - image 1

QA-68

  • UNSPSC Description: QA-68 (QA-68-ZU81) is an effective PROTAC-class BRD9 degrader. QA-68 can inhibit cell cycle progression and cell colony formation. QA-68 has antiproliferative activity against acute myeloid leukemia (AML) cell lines[1]. QA-68 can be formed by a target protein ligand (red part) EA-89 (HY-170314), an E3 ubiquitin ligase ligand (blue part) Lenalidomide-I (HY-131318), and a PROTAC linker (black part) Ethyne-C2-Pip-CO-Pip-Boc (HY-170315). E3 ubiquitin ligase and linker can form Lenalidomide-ethyne-C2-Pip-CO-Pip (HY-170319).
  • Target Antigen: Epigenetic Reader Domain; PROTACs
  • Type: Reference compound
  • Related Pathways: Epigenetics;PROTAC
  • Applications: COVID-19-immunoregulation
  • Field of Research: Cancer; Inflammation/Immunology
  • Assay Protocol: https://www.medchemexpress.com/qa-68.html
  • Solubility: 10 mM in DMSO
  • Smiles: CCCN1C=C(C2=C(C1=O)C=C(C(NC3CCS(CC3)(=O)=O)=O)S2)C4=CC=C(C5=C4)N(C=C5C)CC6CCN(CC6)C(CCC(N7CCN(CC7)C(N8CCN(CC8)CCC#CC9=CC=CC%10=C9CN(C%10=O)C%11CCC(NC%11=O)=O)=O)=O)=O
  • Molecular Weight: 1169.42
  • References & Citations: [1]Weisberg E, et al. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. Blood Cancer J. 2022 Jul 19;12(7):110.
  • Shipping Conditions: Room temperature
  • Clinical Information: No Development Reported